Abstract 36 Table 1

Recurrence of COVID-19 Case Studies

First Author, Year, LocationNumber of subjects with reported recurrent infections/Total N, Age Range (Years)Severity of 1st infectionSeverity of 2nd infectionTime between 1st clinical cure & re-positive RT-PCR test (days)N (%) patients with comorbiditiesOutcome (hospitalization/fatalities) for those with re-positive test
Batisse et al, 2020, France Case series (N=11), Age range=19–91 4/11 (36.4%) mild condition, 7/11 (63.6%) severe 4/11 (36.4%) mild condition, 7/11 (63.6%) severe; 6/7 (85.7%) of severe cases had comorbidities 7–14 for mild cases (4/11), 4–27 for severe cases (7/11) 7/11 (62.6%) 3/11 (27.3%) fatalities: 2 died of ARDS recurrence, 1 from worsening chronic right-heart failure; 3/11 developed no antibodies >21 days after severe symptoms
Ye et al, 2020, China 5/55 (9.1%), Age range=22–67 5/5 (100%) severe condition 5/5 (100%) mild to moderate condition 4–17 0/5 (0%) No fatalities or development of severe pneumonia
Loconsole et al, 2020, Italy Case report, Age 48 1/1 (100%) severe condition 1/1 (100%) severe condition 31 0/1 (0%) No fatality, patient remains on anticoagulation therapy; only IgG antibodies detected during 2nd episode
Ravioli et al, 2020, Switzerland Case reports (n=2), Age range=77–81 2/2 (100%) severe condition 2/2 (100%) severe condition 25 (patient 1) & 19 (patient 2) 2/2 (100%) 1/2 (50%) fatality, 1/2 (50%) hospitalized in COVID-19 isolation ward
Qiao et al, 2020, China 1/15 (6.7%), Age 30 1/1 (100%) severe condition 1/1 (100%) moderate condition 15 Not Reported No fatality
Mei et al, 2020, China 23/651 (3.5%), Age range=27–89 12/23 (52.2%) moderate condition, 9/23 (39.1%) severe, 2/23 (8.7%) critical 15/23 (65.2%) asymptomatic, 8/23 (34.8%) mild to moderate condition 4–38 1/23 (4.3%) 2/23 (8.7%) fatalities from coronary disease and lung disease, 1/23 (4.3%) had cardiac arrest, 5/23 (21.7%) continue isolation and care
Deng et al, 2020, China 61/576 (10.6%), Age range=≤29–79 38/61 (62.3%) mild condition, 20/61 (32.8%) moderate, 3/61 (4.9%) severe 38/61 (62.3%) asymptomatic. 23/61 (37.7%) mild to moderate condition Not Reported 24/61 (39.3%) 22/61 (36.1%) remained hospitalized
Yuan et al, 2020, China 25/172 (14.5%), Age range=≤14–60 25/25 (100%) mild to moderate condition 25/25 (100%) mild condition 7.32 ± 3.86 Not Reported No fatalities
Lafaie et al, 2020, France Case reports (n=3), Age range=84–90 3/3 (100%) severe condition 3/3 (100%) severe condition 12->30 3/3 (100%) 3/3 (100%) fatalities